Integrated Biosciences’ modular platform targets stressed cells via the ISR, hinting at precision strategies for aging therapies.
In a paper published today in Cell, Integrated Biosciences has demonstrated the first application of its optogenetic screening platform, revealing a high degree of control over complex biological pathways and offering a new strategy for probing disease-relevant stress responses. The team, a collaboration between researchers at Integrated Biosciences and several academic institutions, demonstrated their system by selectively activating the Integrated Stress Response (ISR) in human cells – a pathway implicated in viral infection, neurodegeneration and cellular aging.
The approach is striking for both its specificity and restraint: unlike traditional drug discovery tools that often rely on broad chemical stressors or genetic knockouts, this optogenetic system enables millisecond-level temporal control and micron-level spatial control using light. In effect, researchers can switch cellular stress on and off with near-precision and then observe how candidate molecules interact with it – all while avoiding the off-target effects that typically plague phenotypic screens.
Shining a light on stress
The ISR has long attracted attention for its role in cellular homeostasis, but previous attempts to develop ISR modulators have faltered due to cytotoxicity or poor pharmacokinetics. The team’s approach circumvents these issues by enabling pathway-specific activation and readouts that are, according to Dr Maxwell Wilson, Cofounder and Chief Scientific Officer of Integrated Biosciences, “clean, interpretable, and on-pathway.” The team screened more than 370,000 small molecules, ultimately identifying a handful of ISR-potentiating compounds that exhibited broad-spectrum antiviral activity and selective cytotoxicity in stressed, but not healthy, cells [1].
Longevity.Technology: Optogenetics has long promised to bring light to previously intractable biology – Integrated Biosciences’ platform shows that promise starting to materialise in earnest. Rather than just being a marginally better way to screen compounds, this is a finely controlled system for activating specific pathways like the integrated stress response and then observing, in real time, what happens when the balance tips. That it can selectively tip only stressed cells into apoptosis – leaving healthy cells untouched – is striking, and invites comparison with senolytics. But instead of looking for cells that wear senescence markers like a badge, this system hunts down cells quietly waving the biochemical white flag of stress. In the context of aging, that may prove the more precise – and more relevant – signal.
The implications for longevity are bright; stress adaptation is a hallmark of aging biology – a cell’s ability to handle damage, maintain proteostasis and bounce back from adversity tends to degrade long before the telomeres fray. This approach doesn’t blunt the ISR like past efforts; it tunes it, amplifying the terminal signal only in cells already teetering on the edge. Such selectivity suggests the possibility of chronic, low-dose therapies that prune the dysfunctional without systemic collateral damage – precision not just in mechanism but in philosophy. If we are to talk seriously about modifying aging rather than patching up its symptoms, this kind of stress-responsiveness may prove far more valuable than another broad-spectrum ‘antiaging’ hammer.
Mechanism and potential use cases
According to the authors, the compounds act by upregulating ATF4 – a key transcription factor in the ISR – and sensitising cells to apoptosis only in the presence of stressors like thapsigargin or sodium arsenite. One compound, IBX-200, was shown to significantly reduce disease pathology and viral titers in a mouse model of ocular herpesvirus infection. Cellular transcriptomic data revealed increased expression of ISR-related genes including ATF3, DDIT3 (CHOP), and KLF6 – but only under stress-inducing conditions [1].
James J Collins, PhD, Scientific Cofounder of Integrated Biosciences and Termeer Professor at MIT, commented: “This work by the team at Integrated Biosciences is a powerful demonstration of how synthetic biology can reshape therapeutic discovery. Using this novel platform, Integrated Biosciences can now interrogate disease-relevant biology and systematically explore chemical space with a level of nuance and specificity that was previously out of reach.”
“This is only the first demonstration of what our optogenetic platform can do,” said Wilson. “Synthetic biology gives us the control we need to build more accurate, disease-relevant discovery systems. Our goal is to bring this level of precision to other pathways where conventional tools have failed.”
While the ISR has been historically difficult to drug effectively, the authors argue that their “ISR potentiators” avoid the liabilities of previous compounds such as salubrinal or ISRIB, which either suffer from off-target toxicity or limited systemic tolerability. Structural analogues of the IBX series have also shown improved potency, selectivity and favorable toxicity profiles in vitro, according to supplementary data [1].
From antiviral to antiaging?
Though the immediate demonstration focused on viral applications, the broader promise is clear: targeting cellular stress responses – not by shutting them down, but by tuning them – may offer a way to clear dysfunctional cells before they become pathological. This opens a tantalising door for chronic disease intervention strategies that work upstream of symptoms and pathology – particularly in conditions where cumulative cellular stress, not sudden damage, is the driver.
Looking ahead, the modularity of the platform – which might be able to reconfigured for other complex pathways like mTOR or autophagy – makes this a quietly significant development for both longevity science and AI-enabled drug discovery. Aging, after all, is not one disease but many small, accumulating failures of regulation. Perhaps tuning the response, rather than the damage, will prove the more tractable approach.
Images courtesy of Integrated Biosciences
[1] https://www.cell.com/cell/abstract/S0092-8674(25)00690-7
